The global late stage chronic kidney disease therapeutics market has experienced a significant upsurge in recent years, driven by the rising prevalence of CKD worldwide. According to recent market research, the late stage CKD therapeutics market was valued at approximately USD 4.7 Billion in 2019. It is projected to exceed USD 11.1 Billion by 2027, demonstrating a remarkable Compound Annual Growth Rate (CAGR) of around 11.6% during the forecast period from 2022 to 2032.
Chronic kidney disease has emerged as a critical public health concern globally, characterized by its high morbidity and mortality rates. Factors such as diabetes mellitus, hypertension, obesity, and aging are recognized as primary contributors to this fatal condition.
Request A Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9195
The escalating demand for effective therapeutics to manage and treat late stage CKD is driving innovation and investment in the market. With an increasing number of patients being diagnosed with CKD, the need for advanced treatment options is more pressing than ever.
As the market continues to expand, key players in the healthcare and pharmaceutical industries are focusing on developing and delivering cutting-edge therapies to improve patient outcomes and quality of life. The future of CKD treatment looks promising, with ongoing research and development paving the way for more effective and accessible therapeutic solutions.
Late Stage Chronic Kidney Disease Therapeutics Market Poised for Significant Growth Driven by Rising Prevalence and Innovation:
The global market for late-stage chronic kidney disease (CKD) therapeutics is anticipated to experience significant growth in the coming years, fueled by several key factors.
This highlights the major drivers propelling this market expansion:
Rising Global Disease Burden Creates Market Demand:
A critical factor driving market growth is the alarming rise in chronic kidney disease prevalence worldwide. According to a Lancet report, an estimated 700 million people were affected by CKD in 2017, with projections indicating a further surge in the coming years. This increasing disease burden translates to a growing demand for effective treatment options, particularly for patients in late stages.
Market Bolstered by Innovation and Expanding Awareness:
The introduction of novel and advanced late-stage CKD therapeutics is another key growth driver. These innovative solutions offer improved treatment outcomes and address unmet needs in patient care. Additionally, growing awareness among patients and healthcare professionals regarding the benefits of these late-stage therapies is significantly impacting market dynamics.
Favorable Reimbursement Policies and Limited Dialysis Access Create Opportunities:
The establishment of favorable reimbursement policies for CKD treatment by government bodies and healthcare institutions is creating a supportive environment for market expansion. This, coupled with limited access to renal replacement therapy (RRT) and dialysis, particularly in developing nations, paves the way for increased adoption of late-stage CKD therapeutics as a viable treatment alternative.
Request Customization of the Report: https://www.futuremarketinsights.com/customization-available/rep-gb-9195
A Promising Future for Late-Stage CKD Therapeutics:
The confluence of these factors – rising disease prevalence, innovative treatment options, growing awareness, and supportive policies – paints a promising picture for the late-stage chronic kidney disease therapeutics market. This market is well-positioned for robust growth in the foreseeable future.
Key Companies Profiled:
- Amgen
- Deltanoid
- AbbVie
- Sanofi
- Ardelyx
- AstraZeneca
- Kyowa Hakko Kirin
- Genzyme, Keryx
- Spectrum
- Mitsubishi Tanabe
- OPKO Health
- Relypsa
- Shield Therapeutics
- Shire
- Vifor
- ZS Pharma
A Full Report Analysis: https://www.futuremarketinsights.com/checkout/9195
Key Segments Profiled in the Late Stage Chronic Kidney Disease Therapeutics Industry Survey:
By Product Type:
- Calcimimetics
- Sensipar (cinacalcet hydrochloride)
- Vitamin D Sterols
- Nutritional/Native Vitam:in D
- Vitamin D Receptor Agonists
- Phosphate Binders
- Calcium-Based Phosphate Binders
- Aluminum-Containing Phosphate Binders
- Magnesium-Containing Phosphate Binders
- Renvela/Renagel
- Fosrenol (lanthanum carbonate)
- Velphoro (sucroferric oxyhydroxide)
- Auryxia (ferric citrate)
- Potassium Binders
- Resins
- Veltassa (patiromer sorbitex calcium)
By Indication:
- Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- Late Stage Chronic Kidney Disease Induced Hyperkalemia
By End Users:
- Hospital Pharmacy
- Retail Pharmacy
- Mail Order Pharmacy
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- APEJ
- Japan
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube